Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis.

TL;DR: Evaluating the suppressive effects of fluasterone (HE2500), a synthetic androstene derivative, and androstenetriol (HE2200), a natural androstane hormone on EAE suggests that HE2500 and/or HE2200 limit the production of autoimmune Th1 associated cytokines, and ultimately may be beneficial for patients with MS or other autoimmune diseases.

TL;DR: A dysfunction of the hypothalamic – pituitary – adrenal (HPA) axis was found in animal models of chronic inflammatory diseases, and the defect was located in more central portions of the HPA axis.

TL;DR: Continuing investigations suggest that the hypothesis linking susceptibility to autoimmune disease and a hyporesponsive HPA axis is somewhat simplistic, and the link of behavioral differences to alterations in neurotransmitter changes associated with disease is intriguing and opens new avenues of research.

TL;DR: Data reveal that three of the seven patients with RA were able to escape from dexamethasone suppression and mount a cortisol response to CRF challenge, suggesting that there may be a subpopulation of patients with rheumatoid arthritis who have impaired glucocorticoid feedback.

TL;DR: This is an account of further work on a rating scale for depressive states, including a detailed discussion on the general problems of comparing successive samples from a ‘population’, the meaning of factor scores, and the other results obtained.

TL;DR: At the beginning of the second half of the 20th century, most efforts were directed at understanding the molecular and cellular basis of the immune response and the mechanisms of acquisition of immunologic responses.

TL;DR: In this article, the DEX/CRH test was used to assess hypothalamic-pituitary-adrenal-system (HPA) alteration in patients with psychiatric disorders.